NO20092131L - Fettsyrealkoholer - Google Patents

Fettsyrealkoholer

Info

Publication number
NO20092131L
NO20092131L NO20092131A NO20092131A NO20092131L NO 20092131 L NO20092131 L NO 20092131L NO 20092131 A NO20092131 A NO 20092131A NO 20092131 A NO20092131 A NO 20092131A NO 20092131 L NO20092131 L NO 20092131L
Authority
NO
Norway
Prior art keywords
prodrugs
fatty alcohols
omega
relates
polyunsaturated alcohols
Prior art date
Application number
NO20092131A
Other languages
English (en)
Norwegian (no)
Inventor
Anne Kristin Holmeide
Jenny Rosman
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of NO20092131L publication Critical patent/NO20092131L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/24—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO20092131A 2006-11-03 2009-06-02 Fettsyrealkoholer NO20092131L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85626906P 2006-11-03 2006-11-03
US85626706P 2006-11-03 2006-11-03
US85626806P 2006-11-03 2006-11-03
SE0602352 2006-11-03
PCT/IB2007/004590 WO2008139261A2 (en) 2006-11-03 2007-11-02 Omega-3 lipid compound

Publications (1)

Publication Number Publication Date
NO20092131L true NO20092131L (no) 2009-06-30

Family

ID=39876685

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092131A NO20092131L (no) 2006-11-03 2009-06-02 Fettsyrealkoholer

Country Status (10)

Country Link
US (1) US20100266681A1 (enExample)
JP (1) JP2010509204A (enExample)
KR (1) KR20090077081A (enExample)
CN (1) CN101646426A (enExample)
BR (1) BRPI0718393A2 (enExample)
CA (1) CA2667153A1 (enExample)
MX (1) MX2009004339A (enExample)
NO (1) NO20092131L (enExample)
RU (1) RU2009121007A (enExample)
WO (1) WO2008139261A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134147A1 (en) * 2008-05-02 2009-11-05 Pronova Biopharma Norge As Lipid compositions containing derivatives of epa and dha an their use thereof
GB201009368D0 (en) * 2010-06-04 2010-07-21 Sana Pharma As Dietary formulations
WO2012029898A1 (ja) * 2010-09-01 2012-03-08 日本水産株式会社 アルコール性障害緩和剤
BR112014031086A2 (pt) * 2012-06-11 2017-06-27 Cleveland Clinic Found tratamento e prevenção de doenças cardiovasculares e trombose
CN102860506A (zh) * 2012-08-08 2013-01-09 辽宁省大连海洋渔业集团公司 磷虾油微囊粉及其制备方法
US9365482B2 (en) * 2013-02-28 2016-06-14 Pronova Biopharma Norge As Methods of preparing fatty acid derivatives
EP2826384A1 (de) 2013-07-16 2015-01-21 Evonik Industries AG Verfahren zur Trocknung von Biomasse
WO2016050559A1 (de) 2014-10-02 2016-04-07 Evonik Degussa Gmbh VERFAHREN ZUR HERSTELLUNG EINES PUFAs ENTHALTENDEN FUTTERMITTELS DURCH EXTRUSION EINER PUFAs ENTHALTENDEN BIOMASSE
BR112017006833B1 (pt) 2014-10-02 2022-09-13 Evonik Operations Gmbh Alimento para animais contendo ácido graxo poli-insaturado e processo para produzir o mesmo
CA2958463C (en) 2014-10-02 2022-05-03 Evonik Industries Ag Method for raising animals
ES2870093T3 (es) 2014-10-02 2021-10-26 Evonik Operations Gmbh Biomasa que contiene PUFA con estabilidad celular elevada y su empleo para la producción de piensos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01207224A (ja) * 1988-02-10 1989-08-21 Nonogawa Shoji:Kk 頭髪用化粧料及び養毛剤
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
DE60132508T2 (de) * 2000-01-31 2008-04-30 Härting S.A. Zusammensetzungen enthaltend Phytosterol- und Policosanolester von Fettsäuren zur Herabsetzung des Cholesterol- und Triglyceridspiegels
ATE271406T1 (de) * 2000-09-21 2004-08-15 Nutrition 21 Inc Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils
DK1997498T3 (da) * 2001-06-18 2012-07-30 Neptune Technologies & Bioressources Inc Krillekstrakter til forebyggelse og/eller behandling af kardiovaskulære sygdomme
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
CN1665496B (zh) * 2002-05-03 2010-05-05 派普生物保健品公司 Epa和dha在制备二级预防神经性疾患的药物中的用途
AU2003252324A1 (en) * 2002-08-07 2004-03-11 Kao Corporation Fat composition
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
WO2004078166A2 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Also Published As

Publication number Publication date
WO2008139261A9 (en) 2009-11-12
WO2008139261A3 (en) 2009-08-20
WO2008139261A2 (en) 2008-11-20
RU2009121007A (ru) 2010-12-10
CA2667153A1 (en) 2008-11-20
CN101646426A (zh) 2010-02-10
BRPI0718393A2 (pt) 2013-11-26
MX2009004339A (es) 2009-05-20
US20100266681A1 (en) 2010-10-21
KR20090077081A (ko) 2009-07-14
JP2010509204A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
NO20092131L (no) Fettsyrealkoholer
DK2436275T3 (da) Lipidsammensætning til forbedring af hjernefunktion
WO2008036353A3 (en) Omega-3 diglyceride emulsions
ECSP11010746A (es) Salicilatos acetilados con ácidos grasos y sus usos
NZ595599A (en) Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
BR112012020666A2 (pt) "composições de óleo de ácido esteraridônico"
PH12014502412A1 (en) Use of dpa (n-6) oils in infant formula
GB2459809A (en) Fatty acid formulations and methods of use thereof
MX390089B (es) Composiciones de aceite refinado y métodos para su elaboración.
MX2014000770A (es) Composiciones de acidos grasos.
FR2955459B1 (fr) Composition huileuse riche en monoglycerides de dha
BRPI0917942A2 (pt) Óleo contendo um ou mais fosfolipídeos de ácidos graxos poli-insaturados de cadeia longa derivados de biomassa.
DOP2007000029A (es) Composiciones antimicóticas de ramnolípidos y métodos relacionados con su uso
DOP2007000028A (es) Composiciones de ramnolípidos y métodos relacionados con su uso
MX374738B (es) Aceite oxidativamente estable que contiene acidos grasos poliinsaturados.
BR112012015500A2 (pt) composição de combinação útil para o tratamento de doenças cardiovasculares
BR112018009288A8 (pt) composições de triglicerídeos de cadeia média
BRPI0413491A (pt) sistema de gordura vegetal hidrogenada
BRPI0814808B8 (pt) processo para preparação de óleo ou manteiga de sapucainha e uso de óleo ou manteiga de sapucainha
MX2011007188A (es) Metodos para incrementar niveles de plasmalogenos endogenos.
BR112015001616B8 (pt) Método para aumento do teor de sus em um óleo ou em uma fração de oleína por intraesterificação 1,3-específica, óleo ou oleína intraesterificado 1,3-seletivo e seu uso
AR055659A1 (es) Composicion fungicida
HK1201744A1 (en) Composition for improving neuropsychological test battery score

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application